Thomas Madden, et al. Application No.: 09/896,811

Page 15

PENDING CLAIMS

1. (Amended) A liposomal topotecan unit dosage form, said unit dosage form comprising:

a lipid; and

a topotecan dosage of from about 0.01 mg/M²/dose to about 7.5 mg/M²/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

- 2. (Amended) The liposomal topotecan unit dosage form of claim 1, wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.
- 3. The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises a mixture of sphingomyelin and cholesterol.
- 4. The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises sphingomyelin and cholesterol in a ratio by weight of about 30:70 to about 60:40.
- 5. The liposomal topotecan unit dosage form of claim 1, comprising from about 1 $mg/M^2/dose$ to about 4 $mg/M^2/dose$ of topotecan.
- 6. A liposomal topotecan formulation, wherein said liposomal topotecan formulation retains greater than 50% active lactone species after 12 hours in blood circulation.
- 7. The liposomal topotecan formulation of claim 6, wherein said liposomal topotecan formulation retains greater than 80% active lactone species after 12 hours in blood circulation.

Thomas Madden, et al. Application No.: 09/896,811

Page 16

- 8. A liposomal topotecan formulation comprising topotecan, sphingomyelin, cholesterol and a divalent cation ionophore.
- 9. The liposomal topotecan formulation of claim 8, wherein said divalent ionophore is present in trace amounts.
- 10. (Amended) The liposomal topotecan formulation of claim 8, comprising a drug:lipid ratio by weight of about 0.05 to about 0.2.
- 11. (Amended) The liposomal topotecan formulation of claim 10, wherein said drug:lipid ratio by weight is about 0.05 to about 0.15
- 12. The liposomal topotecan formulation of claim 11, comprising trace amounts or greater of a divalent ionophore.
- 13. A method of treating a solid tumor in a human afflicted therewith, said method comprising administering to said human an effective amount of a topotecan dosage of claim 1 in a pharmaceutically acceptable carrier.
- 14. The method of claim 13, wherein said solid tumor is selected from the group consisting of solid tumors of the lung, mammary, colon and prostate.
- 15. The method of claim 13, further comprising co-administration of a treatment for neutropenia or platelet deficiency.
- 16. (Amended) A method of treating solid tumors in a mammal, said method comprising:

administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation having a drug:lipid ratio by weight of about 0.05 to about 0.2.

17. A method of treating solid tumors in a mammal, said method

Thomas Madden, et al. Application No.: 09/896,811

Page 17

comprising:

administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 mg/M²/dose to about 7.5 mg/M²/dose of topotecan for an interval regime, wherein said interval regime is once a day for at least two consecutive days.

- 18. The method of treating solid tumors of claim 17, wherein said interval regime is at least once a week.
- 19. The method of treating solid tumors of claim 17, wherein said interval regime is at least once every two weeks.
- 20. The method of treating solid tumors of claim 17, wherein said interval regime is at least once every three weeks.
- 21. (Amended) The method of treating solid tumors of claim 17, wherein said liposomal topotecan formulation has a drug:lipid ratio by weight of about 0.05 to about 0.2.
- 22. A method of treating solid tumors in a mammal comprising administering to an animal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 to about 7.5 mg/M²/dose of topotecan every three days.
- 23. (Amended) A liposomal camptothecin unit dosage form, said unit dosage form comprising a lipid, a camptothecin dosage of from about 0.015 mg/M²/dose to about 1 mg/M²/dose and having a drug:lipid ratio by weight of about 0.05 to about 0.2.